New pronostic factors in colorectal cancer;Nouveaux facteurs histopronostiques du cancer colorectal

Gastroenterologie Clinique et Biologique

Volumn 26, Issue 5 SUPPL., 2002, Pages

  Piard, Françoise ^a   Martin, Laurent ^a   Chapusot, Caroline ^a   Ponnelle, Tibor ^a   Monges, Geneviève ^b  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b INSTITUT PAOLI CALMETTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; THYMIDYLATE SYNTHASE; CELL ADHESION MOLECULE; CELL SURFACE RECEPTOR; DCC PROTEIN, HUMAN; DNA; DNA BINDING PROTEIN; MICROSATELLITE DNA; SMAD PROTEIN; TRANSACTIVATOR PROTEIN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ANGIOGENESIS; CANCER RESEARCH; CELL PROLIFERATION; CHROMOSOME 18Q; COLORECTAL CANCER; DNA DETERMINATION; HUMAN; MEDICAL LITERATURE; METASTASIS; MICROSATELLITE INSTABILITY; PATIENT CARE; PROGNOSIS; REVIEW; SENTINEL LYMPH NODE; BLOOD; CANCER STAGING; CLASSIFICATION; COLORECTAL TUMOR; GENETICS; METHODOLOGY; MUTATION; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATIENT SELECTION; REPRODUCIBILITY; RISK FACTOR; STANDARD;

CELL ADHESION MOLECULES; COLORECTAL NEOPLASMS; DNA, NEOPLASM; DNA-BINDING PROTEINS; HUMAN; MICROSATELLITE REPEATS; MUTATION; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PATIENT SELECTION; PROGNOSIS; PROTEIN P53; REPRODUCIBILITY OF RESULTS; RISK FACTORS; THYMIDYLATE SYNTHASE; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; HUMANS; RECEPTORS, CELL SURFACE; SMAD PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036297798     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (194)

1. Quels sont les facteurs histopronostiques utiles à la décision thérapeutique dans les cancers du côlon?
2. Recommandations pour la rédaction des comptes-rendus anatomo-pathologiques des cancers coliques
3. International Union Against Cancer
4. Prognostic value of pathological characteristics of colorectal cancer
5. Prognostic factors in colorectal cancer
6. The mesorectum in rectal cancer surgery. The clue to pelvic recurrence?
7. Recurrence and survival after total mesorectal excision for rectal cancer
8. American joint committee on cancer prognostic factors consensus conference: Colorectal working group
9. Prognostic importance of peritoneal involvment on colonic cancer: A prognostic evaluation
10. Detection of free malignant cells in the peritoneal cavity before and after resection of colorectal cancer
11. Allelotype of colorectal carcinomas
12. Multiple genetic alterations in distal and proximal colorectal cancer
13. Microsatellite instability in cancer of the proximal colon
14. DNA-repeat instability is associated with colorectal cancers presenting minimal chromosome rearrangements
15. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer
16. Genetic mapping of a locus predisposing to human colorectal cancer
17. Mutation of hMSH3 and hMSH6 mismatch repair genes in genetically unstable human colorectal and gastric carcinomas
18. Genetic pathways in colorectal and other cancers
19. Hypermethylation of the hMHL1 promoter in colon cancer with microsatellite instability
20. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
21. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes
22. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers
23. Clues to the pathogenesis of familial colorectal cancer
24. Hereditary nonpolyposis colorectal cancer in 95 families: Differences and similarities between mutation-positive and mutation-negative kindreds
25. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer
26. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer
27. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer
28. DNA mismatch repair gene mutations in human cancer
29. Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer
30. The effect of mismatch repair deficiency on tumourigenesis: Microsatellite instability affecting genes containing short repeated sequences
31. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer
32. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability
33. Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells
34. Role of BAX mutations in mismatch repair-deficient colorectal carcinogenesis
35. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype
36. Frameshift mutator mutations
37. Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours
38. CDX2, a human homologue of Drosophila caudal, is mutated in both alleles in a replication error positive colorectal cancer
39. Frameshift mutations at mononucleotide repeats in caspase-5 and other target genes in endometrial and gastrointestinal cancer of the microsatellite mutator phenotype
40. Frequent mutation of the E2F-4 cell cycle in primary human gastrointestinal tumors
41. Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability. Pathobiologic features, hMLH1 and hMSH2 expression, and clinical outcome
42. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences
43. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer
44. Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair
45. Immunohistochemical pattern of hMSH2/hMLH1 in familial and sporadic colorectal, gastric, endometrial and ovarian carcinomas with instability in microsatellite sequences
46. Immunohistochemistry for hMLH1 and hMLH2: A practical test for DNA mismatch repair-deficient tumors
47. Efficient detection of hereditary nonpolyposis colorectal cancer gene carriers by screening for tumor microsatellite instability before germline genetic testing
48. The role of DNA mismatch repair in platinum drug resistance
49. Loss of DNA mismatch repair in acquired resistance to cisplatin
50. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells
51. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers
52. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer
53. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer
54. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: Impact on survival of 388 patients with Dukes'C colon carcinoma
55. Microsatellite instability: Impact on cancer progression in proximal and distal colorectal cancers
56. Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer
57. Molecular predictors of survival after adjuvant chemotherapy for colon cancer
58. Réponse des cancers colorectaux métastatiques au traitement par CPT11 (irinotécan): Implications du système de réparation des mésappariements de base
59. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
60. Overexpression of p53 and long-term survival in colon carcinoma
61. Tp53 and long-term prognosis in colorectal cancer: Mutation in the L3 zinc binding domain predict poor survival
62. Distinct genetic categories and clinical outcome based on proximal or distal tumor location
63. p53 point mutation and survival in colorectal cancer patients: Effect of disease dissemination and tumour location
64. Association of p53 mutations with short survival in colorectal cancer
65. Somatic mutations, acetylator status, and prognosis in colorectal cancer
66. Altered expression of p53 and p27 proteins, alone or combined, as a predictor of metastatic potential in early invasive carcinoma of colon and rectum. A comparative clinicopathologic and molecular analysis
67. Overexpression of cyclin D1 and p53 associated with disease recurrence in colorectal adenocarcinoma
68. Immunohistochemical analysis of p53 in colorectal cancer regarding clinicopathological correlation and prognostic significance
69. p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer
70. Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer
71. p53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance
72. Evaluation of four antibodies in detecting p53 protein for predicting clinicopathological and prognostic significance in colorectal adenocarcinome
73. K-ras mutation and p53 overexpression but not ploidy status predict the clinical behavior of colon cancer
74. p53 nuclear overexpression may not be an independent prognostic marker in early colorectal cancer
75. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest oncology group study
76. The clinical significance of p53 aberrations in human tumours
77. Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma
78. p53 and Rb1 protein expression: Are they prognostically useful in colorectal cancer?
79. p53 alterations are associated with improved prognosis in distal colonic carcinomas
80. Immunohistochemical detection of p53 and Bcl-2 in colorectal carcinoma: No evidence for prognostic significance
81. Overexpression of p53 and long-term survival in colon carcinoma
82. Antibodies against p53 are associated with poor prognosis of colorectal cancer
83. Morphological and genetic abnormalities in prediction of recurrence in radically operated colorectal cancer
84. Relationship among p53, stage, and prognosis of large bowel cancer
85. Prognostic markers for colorectal cancer: Expression of p53 and BCL2
86. Accumulation of p53 in relation to long-term prognosis in colorectal carcinoma
87. Why is p53 protein stabilized in neoplasia? Some answers but many more questions!
88. Roles for p53 in growth arrest and apoptosis: Putting on the brakes after genotoxic stress
89. Tumor-suppressor p53: Implications for tumor development and prognosis
90. Cytoplasmic accumulation of p53 protein: An independent prognostic indicator in colorectal adenocarcinoma
91. Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer. An immunohistochemical analysis
92. p53 mutations are present in colorectal cancer with cytoplasmic p53 accumulation
93. p53 gene mutations inside and outside of exons 5-8: The patterns differ in breast and other cancers
94. Clinical implications of p53 mutations
95. Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinomas
96. p53 gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers
97. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas
98. Prognosis value of p53 genetic changes in colorectal cancer
99. Prognostic significance of p53 abnormalities in colorectal carcinoma detected by PCR-SSCP and immunohistochemical analysis
100. Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinoma
101. The results of colorectal cancer treatment by p53 status. Treatment-specific overview
102. The influence of tumour cell DNA content on survival in colorectal cancer: A detailed analysis
103. Flow cytometric analysis of DNA content in colorectal carcinoma
104. Flow cytometry and image analyses of colorectal adenocarcinomas: A comparative study with clinical correlations
105. DNA densitometry of colorectal cancer
106. DNA ploidy and proliferating cell nuclear antigen in colonic adenomas and adenocarcinomas
107. Prognostic value of DNA ploidy patterns of colorectal adenocarcinomas: Univariate and multivariate analysis
108. Five-year prospective study of DNA tumor ploidy and colorectal cancer survival
109. Tumor ploidy as a risk factor for disease recurrence and short survival in surgically-treated Dukes'B2 colon cancer patients
110. Prognosis significance of DNA ploidy in patients with stage II and stage III colon carcinoma. A prospective flow cytometric study
111. Guidelines for implementation of clinical cytometry
112. Identification of a chromosome 18q gene that is altered in colorectal cancers
113. Allelic loss of chromosome 18q and prognosis in colorectal cancer
114. Prognostic significance of allelic loss at chromosome 18q21 for stage II colorectal cancer
115. The DCC protein and prognosis in colorectal cancer
116. DCC protein as a predictor of distant metastases after curative surgery for rectal cancer
117. Expression of DCC protein in colorectal tumors and its relationship to tumor progression and metastasis
118. Expression of the deleted in colorectal cancer gene is related to prognosis in DNA diploid and low proliferative colorectal adenocarcinoma
119. Mad-related genes in the human
120. DPC4/SMAD4 mediated tumor suppression of colon carcinoma cells is associated with reduced urokinase expression
121. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers
122. TGF-beta receptor signaling
123. TGF-beta signalling from cell membrane to nucleus through SMAD proteins
124. TGF-beta signal transduction
125. Expression of Smad proteins in human colorectal cancer
126. Production and characterization of monoclonal antibodies that localize human thymidilate synthase in the cytoplasm of human cells and tissue
127. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer
128. P53 and thymidylate synthase: Expression in untreated stage II colon cancer: Associations with recurrence, survival, and site
129. Thymidylate synthase expression: An independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer
130. The role of thymidylate synthase levels in the prognosis and the treatment of patients with colorectal cancer
131. Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: Preliminary report from an ongoing trial
132. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin
133. Thymidylate synthase as a predictor of response
134. Thymidilate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: Implication for treatment with fluorouracil
135. Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients
136. Immuno-histochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy
137. Thymidylate synthase protein expression in advanced colon cancer: Correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil
138. Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer
139. Thymidylate synthase and P53 expression predict event free survival but not the response to adjuvant chemotherapy of patients with colonic carcinoma
140. Colorectal liver metastasis thymidylate synthase staining correlates with response to hepatic arterial floxuridine
141. Epitope mapping of a series of human thymidylate synthase monoclonal antibodies
142. Immunohistochemical determination of thymidylate synthase in colorectal cancer-methodological studies
143. Lymphatic mapping and sentinel node biopsy: Is the method applicable to patients with colorectal and gastric cancer?
144. Intraoperative lymphatic mapping and the sentinel node concept in colorectal carcinoma
145. Molecular staging of early colon cancer on the basis of sentinel node analysis: A multicenter phase II trial
146. Lymphatic mapping and focused analysis of sentinel lymph nodes upstage gastrointestinal neoplasms
147. Pathologic evaluation of sentinel lymph nodes in colorectal carcinoma
148. Sentinel lymph node mapping in colorectal cancer. A review
149. Technical details of sentinel lymph node mapping in colorectal cancer and its impact on staging
150. Surgical pathology remains pivotal in the evaluation of "sentinel" lymph nodes
151. Pathologic examination of the sentinel lymph node in malignat melanoma
152. Optimal histopathologic examination of the sentinel lymph node for breast carcinoma staging
153. Accuracy of diagnosis of micrometastases in colorectal cancer by sentinel lymph node mapping technique
154. Intraoperative lymphatic mapping and the sentinel node concept in colorectal carcinoma
155. Focused examination of sentinel lymph nodes upstages early colorectal carcinoma
156. Adjuvant therapy for colorectal cancer
157. Occurrence and prognostic importance of micrometastases in regional lymph nodes in Dukes'B colorectal carcinoma: An immunohistochemical study
158. Prognostic relevance of occult tumor cells in lymph nodes of colorectal carcinomas. An Immunohistochemical study
159. Micrometastasis in colorectal carcinoma: A review
160. Restaging of colorectal cancer based on the identification of lymph node micrometastases through immunoperoxidase staining of CEA and cytokeratins
161. Identification of occult micrometastases in pericolic lymph nodes of Dukes'B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49
162. Genetic diagnosis of lymph-node metastasis in colorectal cancer
163. The prognostic significance of immunohistochemically detected lymph node micrometastases in colorectal carcinoma
164. Micrometastases and survival in stage II colorectal cancer
165. Clinical implications of lymph node micrometastases in patients with colorectal cancers. A case control study
166. Are lymph node micrometastases of any clinical significance in Dukes stages A and B colorectal cancer?
167. Tumour angiogenesis and prognosis
168. Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence
169. Tumor angiogenesis and mode of metastasis in patients with colorectal cancer
170. Tumour angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer
171. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer
172. Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma
173. Tumor angiogenesis in stage II colorectal carcinoma. Association with survival
174. Angiogenesis in colorectal tumors: Microvessel quantitation in adenomas and carcinomas with clinicopathological correlations
175. Prognotic relevance of microvessel density in colorectal tumours
176. Significance of angiogenic factors in liver metastatic tumors originating from colorectal cancers?
177. Tumor angiogenesis predicts recurrence in invasive colorectal cancer when controlled for Dukes staging
178. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors
179. Vascular endothelial growth factor: A key mediator of neoangiogenesis. A review
180. Protein markers in colorectal cancer. Predictors of liver metastasis
181. Angiogenin expression in human colorectal cancer: The role of focal macrophage infiltration
182. Assessment of vascularity in histological sections: Effects of methodology and value as an index of angiogenesis in breast tumours
183. Influence of investigator experience and microscopic field size on microvessel density in node-negative breast carcinoma
184. L'angiogenèse tumorale
185. Retrospective analysis of the prognostic significance of DNA content and proliferative activity in large bowel carcinomas
186. The prognostic significance of proliferating cell nuclear epidermal growth factor receptor, and mdr gene expression in colorectal cancer
187. Prognosis significance of proliferating cell nuclear antigen expression in colorectal cancer
188. Assessment of proliferative activity in carcinomas of the human alimentary tract by Ki-67 immunostaining
189. Proliferating cell nuclear antigen expression and its relationship to malignancy potential in invasive colorectal carcinomas
190. A comparison of proliferation markers (BrdUrd, Ki-67, PCNA) determined at each cell position in the crypts of normal human colonic mucosa
191. Is Ki-67 a better proliferative marker in the colon than proliferating cell nuclear antigen?
192. Immunohistochemical expression of bcl-2 and p53 oncoproteins: Correlation with Ki67 proliferation index and prognostic histopathologic parameters in colorectal neoplasia